ОБЗОР

Поражение печени у больных COVID-19

Информация об авторах

1 Городская больница № 40 Курортного административного района, Санкт-Петербург, Россия

2 Санкт-Петербургский государственный университет, Санкт-Петербург, Россия

Для корреспонденции: Александр Сергеевич Голота
ул. Борисова, д. 9, лит. Б, 197706, г. Санкт-Петербург, Россия; moc.oohay@aatolog

Информация о статье

Вклад авторов: А. С. Голота, Т. А. Камилова — поисково-аналитическая работа, написание текста статьи; Д. А. Вологжанин, С. В. Макаренко, С. Г. Щербак — обсуждение и редактирование текста статьи.

Статья получена: 14.03.2022 Статья принята к печати: 27.03.2022 Опубликовано online: 31.03.2022
|
  1. Skok K, Stelzl E, Trauner M, et al. Post‐mortem viral dynamics and tropism in COVID–19 patients in correlation with organ damage. Virchows Arch. 2021; 478 (2): 343–53. DOI: 10.1007/ s00428-020-02903-8.
  2. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020; 383 (2): 120–8. DOI:10.1056/NEJMoa2015432.
  3. Cabibbo G, Rizzo GEM, Stornello C, Craxì A. SARS-CoV-2 infection in patients with a normal or abnormal liver. J Viral Hepat. 2021; 28 (1): 4–11. DOI: 10.1111/jvh.13440.
  4. Nardo AD, Schneeweiss–Gleixner M, Bakail M, et al. Pathophysiological mechanisms of liver injury in COVID–19. Liver Int. 2021; 41 (1): 20–32. DOI: 10.1111/liv.14730.
  5. Amin М. COVID-19 and the liver: overview. Eur J Gastroenterol Hepatol. 2021; 33 (3): 309–11. DOI: 10.1097/ MEG.0000000000001808.
  6. Yadav DK, Singh A, Zhang Q, et al. Involvement of liver in COVID-19: systematic review and meta–analysis. Gut. 2021; 70 (4): 807–9. DOI: 10.1136/gutjnl-2020-322072.
  7. Kulkarni AV, Kumar P, Tevethia HV, et al. Systematic review with meta–analysis: liver manifestations and outcomes in COVID–19. Aliment Pharmacol Ther. 2020; 52 (4): 584–99. DOI: 10.1111/ apt.15916.
  8. Wang X, Lei J, Li Z, Yan L. Potential Effects of Coronaviruses on the Liver: An Update. Front Med (Lausanne). 2021; 8: 651658. DOI: 10.3389/fmed.2021.651658.
  9. Merola E, Pravadelli C, de Pretis G. Prevalence of liver injury in patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Acta Gastroenterol Belg. 2020; 83 (3): 454–60. PMID: 33094594.
  10. Mohandas S, Vairappan B. SARSCoV2 infection and the gutliver axis. J Dig Dis. 2020; 21 (12): 687–95. DOI: 10.1111/17512980.12951.
  11. Li Y, Xiao SY. Hepatic involvement in COVID-19 patients: Pathology, pathogenesis, and clinical implications. J Med Virol. 2020; 92 (9): 1491–4. DOI: 10.1002/jmv.25973.
  12. Butikofer S, Lenggenhager D, Wendel Garcia PD, et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID19. Liver Int. 2021; 41 (10): 2404–17. DOI: 10.1111/liv.14971.
  13. McConnell MJ, Kondo R, Kawaguchi N, Iwakiri Y. COVID-19 and liver injury: role of inflammatory endotheliopathy, platelet dysfunction and thrombosis. Hepatol Commun. 2022; 6 (2): 255– 69. DOI: 10.1002/hep4.1843.
  14. Kaur S, Hussain S, Kolhe K, et al. Elevated plasma ICAM1 levels predict 28-day mortality in cirrhotic patients with COVID-19 or bacterial sepsis. JHEP Rep. 2021; 3 (4): 100303. DOI: 10.1016/j.jhepr.2021.100303.
  15. Zhao J-N, Fan Y, Wu S-D. Liver injury in COVID-19: A minireview. World J Clin Cases. 2020; 8 (19): 4303–10. DOI: 10.12998/wjcc. v8.i19.4303.
  16. Beigmohammadi MT, Jahanbin B, Safaei M, et al. Pathological findings of postmortem biopsies from lung, heart, and liver of 7 deceased COVID-19 patients. Int J Surg Pathol. 2021; 29 (2): 135–45. DOI: 10.1177/1066896920935195.
  17. Fanni D, Cerrone G, Saba L, et al. Thrombotic sinusoiditis and local diffuse intrasinusoidal coagulation in the liver of subjects affected by COVID-19: the evidence from histology and scanning electron microscopy. Eur Rev Med Pharmacol Sci. 2021; 25 (19): 5904–12. DOI: 10.26355/eurrev_202110_26866.
  18. Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020; 73 (4): 807–16. DOI: 10.1016/j. jhep.2020.05.002.
  19. Schmit G, Lelotte J, Vanhaebost J, et al. The liver in COVID-19related death: protagonist or innocent bystander? Pathobiology. 2021; 88 (1): 88–94. DOI: 10.1159/000512008.
  20. Cai Q, Huang D, Yu H, et al. COVID-19: abnormal liver function tests. J Hepatol. 2020; 73 (3): 566–74. DOI: 10.1016/j. jhep.2020.04.006.
  21. Stebbing J, Sanchez Nievas G, Falcone M, et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2021; 7 (1): eabe4724. DOI: 10.1126/sciadv.abe4724.
  22. Kim WY, Kweon OJ, Cha MJ, et al. Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study. PLoS One. 2021; 16 (7): e0254167. DOI: 10.1371/journal.pone.0254167.
  23. Raschi E, Caraceni P, Poluzzi E, De Ponti F. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19? Expert Opin Drug Saf. 2020; 19: 1367–69. DOI: 10.1080/14740338.2020.1812191.
  24. Naeem A, Khamuani MK, Kumar P, et al. Impact of coronavirus diseases on liver enzymes. Cureus. 2021; 13 (9): e17650. DOI: 10.7759/cureus.17650.
  25. Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021; 74 (4): 944–51. 10.1016/j. jhep.2021.01.032.
  26. Hundt MA, Deng Y, Ciarleglio MM, et al. Abnormal liver tests in COVID–19: a retrospective observational cohort study of 1827 patients in a major U.S. hospital network. Hepatology. 2020; 72 (4): 1169–76. DOI: 10.1002/HEP.31487.
  27. Pirisi M, Rigamonti C, D’Alfonso S, et al. Liver infection and COVID-19: the electron microscopy proof and revision of the literature. Eur Rev Med Pharmacol Sci. 2021; 25 (4): 2146–51. DOI: 10.26355/eurrev_202102_25120.
  28. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395 (10234): 1417–18. DOI: 10.1016/S0140-6736(20)30937-5.
  29. Duarte-Neto AN, Monteiro RA, da Silva LF, et al. Pulmonary and systemic involvement in COVID-19 patients assessed with ultrasound-guided minimally invasive autopsy. Histopathology. 2020; 77: 186–97. DOI: 10.1111/his.14160.
  30. Sonzogni A, Previtali G, Seghezzi M, et al. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. Liver Int. 2020; 40 (9): 2110–16. DOI: 10.1111/ liv.14601.
  31. Fogarty H, Townsend L, Morrin H, et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost. 2021; 19 (10): 2546–53. DOI: 10.1111/jth.15490.
  32. Rapkiewicz A, Carsons S, Pittaluga S, et al. Megakaryocytes and platelet–fibrin thrombi characterize multi–organ thrombosis at autopsy in COVID–19: A case series. EClinicalMedicine. 2020; 24: 100434. DOI: 10.1016/j.eclinm.2020.100434.
  33. Musa S. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now? Arab J Gastroenterol. 2020; 21 (1): 3–8. DOI: 10.1016/j.ajg.2020.03.002.
  34. Chen LY, Chu HK, Bai T, et al. Liver damage at admission is an independent prognostic factor for COVID-19. J Dig Dis. 2020; 21 (9): 512–18. DOI: 10.1111/1751-2980.12925.
  35. Mushtaq K, Khan MU, Iqbal F, et al. NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression — The debate continues. J Hepatol. 2021; 74 (2): 482–84. DOI: 10.1016/j.jhep.2020.09.006.
  36. Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID–19–related hospital death in the linked electronic health records of 17 million adult NHS patients. Nature. 2020; 584 (7821): 430–36. DOI: 10.1038/s41586-020-2521-4.
  37. Barry A, Apisarnthanarax S, O'Kane GM, et al. Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. Lancet Gastroenterol Hepatol. 2020; 5 (8): 765–75. DOI: 10.1016/S2468-1253(20)30182-5.
  38. Gosain R, Abdou Y, Singh A, et al. COVID-19 and cancer: a comprehensive review. Curr Oncol Rep. 2020. 8; 22 (5): 53. DOI: 10.1007/s11912-020-00934-7.
  39. D'Antiga L. Coronaviruses and immunosuppressed patients: the facts during the Third Epidemic. Liver Transpl. 2020; 26 (6): 832– 4. DOI: 10.1002/lt.25756.
  40. SECURE CIRRHOSIS REGISTRY. https: //covidcirrhosis.web. unc.edu/updates-and-data/. Accessed 14.12.2021.
  41. Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol. 2021; 74 (3): 567–77. DOI: 10.1016/j.jhep.2020.09.024.
  42. Cheung KS, Hung IFN, Chan PPY, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta– analysis. Gastroenterology. 2020; 159 (1): 81–95. DOI: 10.1053/j. gastro.2020.03.065.
  43. Amirian ES. Potential fecal transmission of SARS-CoV-2: Current Evidence and Implications for Public Health. Int J Infect Dis. 2020; 95: 363–70. DOI: 10.1016/j.ijid.2020.04.057.
  44. Han D, Fang Q, Wang X. SARS-CoV-2 was found in the bile juice from a patient with severe COVID-19. J Med Virol. 2021; 93 (1): 102–4. DOI: 10.1002/jmv.26169.
  45. Vespa E, Pugliese N, Colapietro F, Aghemo A. STAY (GI) HEALTHY: COVID-19 and gastrointestinal manifestations. Tech Innov Gastrointest Endosc. 2021; 23 (2): 179–89. DOI: 10.1016/j. tige.2021.01.006.
  46. Filbin MR, Mehta A, Schneider AM, et al. Longitudinal proteomic analysis of severe COVID-19 reveals survivalassociated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med. 2021; 2 (5): 100287. DOI: 10.1016/j. xcrm.2021.100287.